Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 5/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 2/20 | 0.41 |
| ▸ | FNTB | P49356 | 2/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14355378 | 0.86 | ATM (0.57) | DPP4DPP7DPP8DPP9CCR3 | |
| SCHEMBL8282124 | 0.84 | F2 (0.47) | F2DPP4DPP7DPP8DPP9 | |
| SCHEMBL8279784 | 0.84 | ADRB2 (0.50) | F2DPP4DPP7DPP8DPP9 | |
| SCHEMBL8280943 | 0.82 | CHRM2 (0.54) | DPP4HDAC8 | |
| SCHEMBL8282125 | 0.81 | AKR1C3 (0.52) | F2HDAC8 | |
| SCHEMBL14355374 | 0.80 | HDAC8 (0.45) | F2DPP4DPP7DPP8DPP9 | |
| SCHEMBL5571269 | 0.80 | HDAC8 (0.45) | F2DPP4DPP7DPP8DPP9 | |
| SCHEMBL5188797 | 0.80 | HDAC8 (0.45) | F2DPP4DPP7DPP8DPP9 | |
| SCHEMBL8281700 | 0.80 | HDAC8 (0.41) | F2DPP4DPP7DPP8DPP9 | |
| SCHEMBL5187640 | 0.79 | DPP4 (0.60) | F2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265261-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-15 | — | — | US | disclosed |
| US-20070265261-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-15 | — | — | US | disclosed |
| WO-2005121089-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265261-A1 | Dpp-IV Inhibitors | DPP4, DPP3, DPP7 | F2 1775/4885DPP4 1/4885DPP7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.